Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease.


Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 07 12 2020
accepted: 25 02 2021
pubmed: 15 4 2021
medline: 19 8 2021
entrez: 14 4 2021
Statut: ppublish

Résumé

The ongoing pandemic caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2) has stressed health systems worldwide. Patients with chronic kidney disease (CKD) seem to be more prone to a severe course of coronavirus disease (COVID-19) due to comorbidities and an altered immune system. The study's aim was to identify factors predicting mortality among SARS-CoV-2-infected patients with CKD. We analyzed 2817 SARS-CoV-2-infected patients enrolled in the Lean European Open Survey on SARS-CoV-2-infected patients and identified 426 patients with pre-existing CKD. Group comparisons were performed via Chi-squared test. Using univariate and multivariable logistic regression, predictive factors for mortality were identified. Comparative analyses to patients without CKD revealed a higher mortality (140/426, 32.9% versus 354/2391, 14.8%). Higher age could be confirmed as a demographic predictor for mortality in CKD patients (> 85 years compared to 15-65 years, adjusted odds ratio (aOR) 6.49, 95% CI 1.27-33.20, p = 0.025). We further identified markedly elevated lactate dehydrogenase (> 2 × upper limit of normal, aOR 23.21, 95% CI 3.66-147.11, p < 0.001), thrombocytopenia (< 120,000/µl, aOR 11.66, 95% CI 2.49-54.70, p = 0.002), anemia (Hb < 10 g/dl, aOR 3.21, 95% CI 1.17-8.82, p = 0.024), and C-reactive protein (≥ 30 mg/l, aOR 3.44, 95% CI 1.13-10.45, p = 0.029) as predictors, while renal replacement therapy was not related to mortality (aOR 1.15, 95% CI 0.68-1.93, p = 0.611). The identified predictors include routinely measured and universally available parameters. Their assessment might facilitate risk stratification in this highly vulnerable cohort as early as at initial medical evaluation for SARS-CoV-2.

Identifiants

pubmed: 33851328
doi: 10.1007/s15010-021-01597-7
pii: 10.1007/s15010-021-01597-7
pmc: PMC8043429
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-737

Investigateurs

Lukas Tometten (L)
Kai Wille (K)
Siegbert Rieg (S)
Stefan Borgmann (S)
Matthias Wettstein (M)
Nora Isberner (N)
Maria Ruethrich (M)
Christoph Spinner (C)
Claudia Raichle (C)
Mark Neufang (M)
Frank Hanses (F)
Bernd Hohenstein (B)
Sven Stieglitz (S)
Norma Jung (N)
Robert Bals (R)
Sebastian Dolff (S)
Joerg Schubert (J)
Maximilian Worm (M)
Christian Degenhardt (C)
Timo Brandenburger (T)
Julia Fuerst (J)
Maria Vehreschild (M)
Ulrich Keller (U)
Martin Hower (M)
Michael von Bergwelt-Baildon (M)
Jessica Rueddel (J)
Katja de With (K)
Beate Gruener (B)
Lukas Eberwein (L)
Beate Schultheis (B)
David Heigener (D)
Wolfgang Guggemos (W)
Helga Peetz (H)
Lorenz Walter (L)
Juergen Prattes (J)
Katja Rothfuss (K)
Kerstin Hellwig (K)
Jacob Nattermann (J)
Uta Merle (U)
Daniel Droehmann (D)
Dominic Rauschning (D)
Gabriele Mueller-Joerger (G)
Alexander Weidemann (A)
Christiane Piepel (C)
Annika Ritter (A)
Gernot Beutel (G)
Janina Trauth (J)
Anette Friedrichs (A)
Wolfgang Bethge (W)
Joerg Janne Vehreschild (JJ)
Lisa Pilgram (L)
Melanie Stecher (M)
Maximilian Schons (M)
Carolin E M Jakob (CEM)
Annika Classen (A)
Sandra Fuhrmann (S)
Bernd Franke (B)
Nick Schulze (N)
Fabian Prasser (F)
Martin Lablans (M)

Informations de copyright

© 2021. The Author(s).

Références

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9. https://doi.org/10.1001/jama.2020.1585 .
doi: 10.1001/jama.2020.1585 pubmed: 32031570 pmcid: 32031570
Pan XW, Xu D, Zhang H, Zhou W, Wang LH, Cui XG. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 2020;46:1114–6. https://doi.org/10.1007/s00134-020-06026-1 .
doi: 10.1007/s00134-020-06026-1 pubmed: 32236644
Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, et al. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol. 2006;291:H2166–72. https://doi.org/10.1152/ajpheart.00061.2006 .
doi: 10.1152/ajpheart.00061.2006 pubmed: 16766648
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4. https://doi.org/10.1038/nature02145 .
doi: 10.1038/nature02145 pubmed: 14647384 pmcid: 7095016
Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004;203:622–30. https://doi.org/10.1002/path.1560 .
doi: 10.1002/path.1560 pubmed: 15141376 pmcid: 7167761
Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98:219–27. https://doi.org/10.1016/j.kint.2020.04.003 .
doi: 10.1016/j.kint.2020.04.003 pubmed: 32327202 pmcid: 32327202
Trabulus S, Karaca C, Balkan II, Dincer MT, Murt A, Ozcan SG, et al. Kidney function on admission predicts in-hospital mortality in COVID-19. PLoS ONE. 2020;15:e0238680. https://doi.org/10.1371/journal.pone.0238680 .
doi: 10.1371/journal.pone.0238680 pubmed: 32881976 pmcid: 7470363
Xia P, Wen Y, Duan Y, Su H, Cao W, Xiao M, et al. Clinicopathological features and outcomes of acute kidney injury in critically Ill COVID-19 with prolonged disease course: a retrospective cohort. J Am Soc Nephrol. 2020;31:2205–21. https://doi.org/10.1681/ASN.2020040426 .
doi: 10.1681/ASN.2020040426 pubmed: 32826326
Portoles J, Marques M, Lopez-Sanchez P, de Valdenebro M, Munez E, Serrano ML, et al. Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol Dial Transplant. 2020;35:1353–61. https://doi.org/10.1093/ndt/gfaa189 .
doi: 10.1093/ndt/gfaa189 pubmed: 32871592
Rapp J, Lieberman-Cribbin W, Tuminello S, Taioli E. Male sex, severe obesity, older age, and chronic kidney disease are associated with COVID-19 severity and mortality in New York City. Chest. 2020. https://doi.org/10.1016/j.chest.2020.08.2065 .
doi: 10.1016/j.chest.2020.08.2065 pubmed: 32866462
Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol. 2020. https://doi.org/10.1038/s41581-020-00349-4 .
doi: 10.1038/s41581-020-00349-4 pubmed: 32848205 pmcid: 7447963
Seidel M, Holzer B, Appel H, Babel N, Westhoff TH, Group CDW. Impact of renal disease and comorbidities on mortality in hemodialysis patients with COVID-19: a multicenter experience from Germany. J Nephrol. 2020. https://doi.org/10.1007/s40620-020-00828-8 .
doi: 10.1007/s40620-020-00828-8 pubmed: 32804355 pmcid: 7429939
Jakob CEM, Borgmann S, Duygu F, Behrends U, Hower M, Merle U, et al. First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS).” Infection. 2020. https://doi.org/10.1007/s15010-020-01499-0 .
doi: 10.1007/s15010-020-01499-0 pubmed: 33001409 pmcid: 7527665
Fried MW, Crawford JM, Mospan AR, Watkins SE, Munoz Hernandez B, Zink RC, et al. Patient characteristics and outcomes of 11,721 patients with COVID19 hospitalized across the United States. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1268 .
doi: 10.1093/cid/ciaa1268
Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8:853–62. https://doi.org/10.1016/S2213-2600(20)30316-7 .
doi: 10.1016/S2213-2600(20)30316-7 pubmed: 32735842 pmcid: 7386882
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3 .
doi: 10.1016/S0140-6736(20)30566-3 pubmed: 32171076 pmcid: 32171076
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. https://doi.org/10.1136/bmj.m1966 .
doi: 10.1136/bmj.m1966 pubmed: 7243801 pmcid: 7243801
Mackey K, King VJ, Gurley S, Kiefer M, Liederbauer E, Vela K, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020;173:195–203. https://doi.org/10.7326/M20-1515 .
doi: 10.7326/M20-1515 pubmed: 32422062
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431–40. https://doi.org/10.1056/NEJMoa2006923 .
doi: 10.1056/NEJMoa2006923 pubmed: 32356627
Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020. https://doi.org/10.1016/j.kint.2020.07.030 .
doi: 10.1016/j.kint.2020.07.030 pubmed: 33301749 pmcid: 7428720
Cecile C, Florian B, Carole A, Clemence B, Philippe B, Francois C, et al. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. Kidney Int. 2020. https://doi.org/10.1016/j.kint.2020.07.042 .
doi: 10.1016/j.kint.2020.07.042
Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. medRxiv. 2020. https://doi.org/10.1101/2020.04.15.20067157 .
doi: 10.1101/2020.04.15.20067157 pubmed: 33398298 pmcid: 7781341
Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382:2372–4. https://doi.org/10.1056/NEJMc2010419 .
doi: 10.1056/NEJMc2010419 pubmed: 32302078
Berenguer J, Ryan P, Rodriguez-Bano J, Jarrin I, Carratala J, Pachon J, et al. Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.07.024 .
doi: 10.1016/j.cmi.2020.07.024 pubmed: 32860964 pmcid: 7449935
Tao Z, Xu J, Chen W, Yang Z, Xu X, Liu L, et al. Anaemia is associated with severe illness in COVID-19: a retrospective cohort study. J Med Virol. 2020. https://doi.org/10.1002/jmv.26444 .
doi: 10.1002/jmv.26444 pubmed: 32949174 pmcid: 7461066
Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18:1469–72. https://doi.org/10.1111/jth.14848 .
doi: 10.1111/jth.14848 pubmed: 32302435
Maquet J, Lafaurie M, Sommet A, Moulis G. Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. Br J Haematol. 2020;190:e276–9. https://doi.org/10.1111/bjh.16950 .
doi: 10.1111/bjh.16950 pubmed: 32557535
Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2020. https://doi.org/10.1038/s41569-020-00469-1 .
doi: 10.1038/s41569-020-00469-1 pubmed: 33214651 pmcid: 7675396

Auteurs

Lisa Pilgram (L)

Department of Internal Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.

Lukas Eberwein (L)

4th Department of Internal Medicine, Klinikum Leverkusen gGmbH, Leverkusen, Germany.

Kai Wille (K)

University Clinic for Haematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Klinikum, University of Bochum, Minden, Germany.

Felix C Koehler (FC)

Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Faculty of Medicine and University Hospital Cologne, CECAD, University of Cologne, Cologne, Germany.
Emergency Department, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Melanie Stecher (M)

Department I of Internal Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany.
German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.

Siegbert Rieg (S)

Division of Infectious Diseases, Department of Medicine II, Medical Centre - University of Freiburg, Faculty of Medicine, Freiburg, Germany.

Jan T Kielstein (JT)

Medical Clinic V, Academic Teaching Hospital Braunschweig, Brunswick, Germany.

Carolin E M Jakob (CEM)

Department I of Internal Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany.
German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.

Maria Rüthrich (M)

Department of Internal Medicine II, University Hospital Jena, Jena, Germany.

Volker Burst (V)

Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Emergency Department, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Fabian Prasser (F)

Charite, University Hospital Berlin, Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Stefan Borgmann (S)

Department of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany.

Roman-Ulrich Müller (RU)

Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Faculty of Medicine and University Hospital Cologne, CECAD, University of Cologne, Cologne, Germany.
Systems Biology of Ageing Cologne (Sybacol), University of Cologne, Cologne, Germany.

Julia Lanznaster (J)

Department of Internal Medicine 2, Klinikum Passau, Passau, Germany.

Nora Isberner (N)

Division of Infectious Diseases, Department of Medicine II, University of Würzburg Medical Center, Würzburg, Germany.

Lukas Tometten (L)

Department of Gastroenterology and Infectiology, Klinikum Ernst-von-Bergmann, Potsdam, Germany.

Sebastian Dolff (S)

Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Germany. Sebastian.Dolff@uk-essen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH